CatView Visual guide Catheter Moshe Refael, CEO January 2016 Business presentation by

Company Overview CatView was founded in Jun 2015 The Team: –Moshe Refael CEO - Serial entrepreneur, an expert in electro- optical technology and image processing. –Prof. Ariel Roguin, Head of Cathe. Dept, Rambam Hospital –Prof. Steve Lipson. Optical specialist, Technion, Haifa –Dr. Yaron Hefetz, Specialist in fiber optics – GE, Haifa –The first generation product under development: Viewing Guide Catheter

The Company CatView is planned to be a leader in the world-wide medical optics community The first product to be developed is: A flexible Viewing Catheter for Coronary Arteries. in a period of 24 months. Next step to be developed : A conducting Catheter

The Problem Part # 1 People need to undergo arterial catheter inspection. The procedure uses contrast materials. The contrast materials damage the kidneys….

The solution Developing a Catheter guide with real-time visual observation capabilities, without using contrast materials 1.Avoiding kidney damage and destruction. 2.Shortening the whole procedure.

The problem Part # 2 - Tech 1. Scattering of light by the blood. 2. The transparency of the blood results in a maximum observing distance about 1.2mm. 3. Sensor saturation problem. 4. To provide an SVGA image with a few optical fibers.

The solution Introducing clear physiological fluid during the procedure. Locally clearing the red blood cells. Creating a clear environment – making it possible to take clear pictures

Progression of the disease problem - 1.People who suffer from overweight. 2.The majority will develop diabetes + heart disease. 3.Leading into renal insufficiency. 4.During the treatment contrast materials and other chemicals are needed, which aggravate the kidney situation 5.So on ….

First step to be developed: A new Coronary\Artery Catheter which will change the whole procedural method. Our main goal is to develop a disposable Visual Catheter\guide with a user price of about $ 150 A Visual Guide Catheter

The Market WW in 1995 $ 640 Million In 2004 in USA $ 4 Billion. In 2014 in USA $ 11 Billion. The market consistently grows

Heart Attack-Epidemiology WHY A GUIDE FOR HEART SURGERY?  The most fatal disease in males.  The second most fatal disease after breast cancer, is the cardiac arrest in women. 80% of the patients will die without early diagnosis

12 Exponential Growth in Catheter treatments –4.5K Procedures WW, in 1989 –1M Procedures WW, in 1999 –16M Procedures WW, in 2015 –100% of procedures are done in hospital clinics –In Israel in 2015 there were 55,000 procedures in 40 clinics

Potential Strategic Partnerships In USA In Europe J & JB. Braun Boston ScientificSiemens Medical division CookSchott Medtronic Stryker

The Catheter

15 Today’s Catheter Procedure Recovery Room Prep. Room Procedure Room 30 minutes 60 minutes hours We assume and wish that: With our new Catheter guide. the whole procedure will be shorted from 60 Minutes into 30 minutes

Reimbursement The reimbursement support the MD’s clinic with $ 345 per procedure By suggesting a unit costing about $ 150, the clinic earns $ 200 per procedure

CatView IP innovation Using just a few fibers, an optical guide with real time visual abilities will minimize use of contrast materials and reduce kidney impact almost to zero

Financial Projection for development Year # 1 $ 500 K Year #2 $ 1.5 M 1.Complete Feasibility product 2.Helsinki approval 3.Start Animal trials 4.Prototype design 1.Start FDA path 2.Industrial product design 1. Strategic partnership 2. Animal approval 3. Raising $ 10 M for year 4 FDA approval Year # 3 - 4

Needs & Goals Graph ($) Year Positioned & running in 20 Clinics with 150K units Raise $500 K Raise $ 1.5M For Final the product: Camera, + prototype Raise $10 M Start point Animals trials β status = FDA Human trials 5 First Sales

The Success of Cat View depends on meeting the following: Costs Table –BOM – $ 13 –COGS - $ 21 –Ex- Factory- $ 80 –End User Price ~ $ 150 The work station will be provided almost for free

Expected Company Valuation $ Years 20 Clinics running & 150 K units WW Value of $ 1 M Value of $ 5M Value of $ 50 M Value Expected of $ 350M β status = FDA Human tries Complete the Camera + prototype Animals trials

Action Plan 1.Improvement of current prototype 2.Beginning imaging board design and evaluation 3.Beginning evaluation of FDA pathway 4.Animal trials – Helsinki approval First 12 month 1.Completion of  version of the product 2.Filing 510k request to FDA and ISO/CE compliance 3.Approval of human clinical trials 4.Planning and starting  version production line 5.Strategic partnership and “scientific” marketing through opinion leaders 13 – 24 Month 1.FDA and CE approval 2.Production of  version (semi mass-production) 3.Sales and market development 4.Setting mass-production line

Gantt * Optical design software, Fibers, Camera board, optics, pump, joystick ** marketing = Raising money

Thank You